Impact of disease status among adult Ph+ ALL patients undergoing unrelated allo-HCT during CR1 or CR2: multivariate analyses
| Covariate . | HR . | 95% CI . | P . |
|---|---|---|---|
| OS | |||
| Age ≥55 y at allo-HCT (vs ≥16 and <55 y) | 1.51 | 1.27-1.81 | <.001 |
| PS 1-4 (vs 0) | 1.31 | 1.11-1.54 | .002 |
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.25 | 1.06-1.47 | .01 |
| Year of allo-HCT 2013-2017 (vs 2002-12) | 0.79 | 0.65-0.95 | .01 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.80 | 1.50-2.16 | <.001 |
| CR2 MRD− | 2.01 | 1.38-2.94 | <.001 |
| CR2 MRD+ | 2.37 | 1.59-3.55 | <.001 |
| LFS | |||
| Age ≥55 y at allo-HCT (vs ≤16 and < 55 y) | 1.39 | 1.13-1.72 | .002 |
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.35 | 1.16-1.58 | <.001 |
| Preparative regimen of VP + CY + TBI (vs other) | 0.64 | 0.48-0.85 | .002 |
| Year of allo-HCT 2013-2017 (vs 2002-2012) | 0.84 | 0.71-0.996 | .045 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.82 | 1.54-2.16 | <.001 |
| CR2 MRD− | 1.64 | 1.14-2.36 | .008 |
| CR2 MRD+ | 2.61 | 1.77-3.85 | <.001 |
| Relapse | |||
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.43 | 1.14-1.80 | .002 |
| Donor (vs related) | |||
| UBM | 0.68 | 0.52-0.88 | .003 |
| UCB | 0.62 | 0.46-0.85 | .003 |
| Preparative regimen of VP + CY + TBI (vs other) | 0.47 | 0.30-0.75 | .001 |
| Posttransplantation TKI (vs none) | 2.34 | 1.70-3.21 | <.001 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.82 | 1.42-2.33 | <.001 |
| CR2 MRD− | 1.27 | 0.69-2.32 | .44 |
| CR2 MRD+ | 3.87 | 2.31-6.49 | <.001 |
| NRM | |||
| Age ≥55 y at allo-HCT (vs ≤16 and <55 y) | 1.67 | 1.34-2.08 | <.001 |
| PS 1-4 (vs 0) | 1.35 | 1.09-1.66 | .005 |
| Donor (vs related) | |||
| UBM | 1.54 | 1.19-2.00 | .001 |
| UCB | 1.38 | 1.02-1.87 | .04 |
| Posttransplantation TKI (vs none) | 0.50 | 0.29-0.86 | .01 |
| Year of allo-HCT 2013-2017 (vs 2002-2012) | 0.76 | 0.60-0.95 | .02 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.54 | 1.22-1.95 | <.001 |
| CR2 MRD− | 1.66 | 1.04-2.66 | .04 |
| CR2 MRD+ | 1.23 | 0.65-2.34 | .53 |
| Covariate . | HR . | 95% CI . | P . |
|---|---|---|---|
| OS | |||
| Age ≥55 y at allo-HCT (vs ≥16 and <55 y) | 1.51 | 1.27-1.81 | <.001 |
| PS 1-4 (vs 0) | 1.31 | 1.11-1.54 | .002 |
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.25 | 1.06-1.47 | .01 |
| Year of allo-HCT 2013-2017 (vs 2002-12) | 0.79 | 0.65-0.95 | .01 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.80 | 1.50-2.16 | <.001 |
| CR2 MRD− | 2.01 | 1.38-2.94 | <.001 |
| CR2 MRD+ | 2.37 | 1.59-3.55 | <.001 |
| LFS | |||
| Age ≥55 y at allo-HCT (vs ≤16 and < 55 y) | 1.39 | 1.13-1.72 | .002 |
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.35 | 1.16-1.58 | <.001 |
| Preparative regimen of VP + CY + TBI (vs other) | 0.64 | 0.48-0.85 | .002 |
| Year of allo-HCT 2013-2017 (vs 2002-2012) | 0.84 | 0.71-0.996 | .045 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.82 | 1.54-2.16 | <.001 |
| CR2 MRD− | 1.64 | 1.14-2.36 | .008 |
| CR2 MRD+ | 2.61 | 1.77-3.85 | <.001 |
| Relapse | |||
| WBC count ≥30 × 103/μL at diagnosis (vs <30 × 103/μL) | 1.43 | 1.14-1.80 | .002 |
| Donor (vs related) | |||
| UBM | 0.68 | 0.52-0.88 | .003 |
| UCB | 0.62 | 0.46-0.85 | .003 |
| Preparative regimen of VP + CY + TBI (vs other) | 0.47 | 0.30-0.75 | .001 |
| Posttransplantation TKI (vs none) | 2.34 | 1.70-3.21 | <.001 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.82 | 1.42-2.33 | <.001 |
| CR2 MRD− | 1.27 | 0.69-2.32 | .44 |
| CR2 MRD+ | 3.87 | 2.31-6.49 | <.001 |
| NRM | |||
| Age ≥55 y at allo-HCT (vs ≤16 and <55 y) | 1.67 | 1.34-2.08 | <.001 |
| PS 1-4 (vs 0) | 1.35 | 1.09-1.66 | .005 |
| Donor (vs related) | |||
| UBM | 1.54 | 1.19-2.00 | .001 |
| UCB | 1.38 | 1.02-1.87 | .04 |
| Posttransplantation TKI (vs none) | 0.50 | 0.29-0.86 | .01 |
| Year of allo-HCT 2013-2017 (vs 2002-2012) | 0.76 | 0.60-0.95 | .02 |
| Status at allo-HCT (vs CR1 MRD−) | |||
| CR1 MRD+ | 1.54 | 1.22-1.95 | <.001 |
| CR2 MRD− | 1.66 | 1.04-2.66 | .04 |
| CR2 MRD+ | 1.23 | 0.65-2.34 | .53 |
CY, cyclophosphamide; HR, hazard ratio; TBI, total body irradiation; UBM, unrelated bone marrow or peripheral blood; UCB, unrelated cord blood; VP, etoposide.